DENVER, Colo., Nov 20, 2025 (247marketnews.com)- U.S. equity futures are being driven by a $21 billion healthcare megadeal to significant financial turnarounds, emerging-tech milestones, and the completion of a closely watched restatement in the post-acute care sector.
PACS Group (NYSE:PACS) Reasserts Stability as Q3 Results Surge
PACS Group opened the day with one of the most anticipated updates in the post-acute care industry, announcing Q3 2025 revenue of $1.34 billion, up 31% from last year. The company also completed its financial restatement, is now fully current on all SEC filings, and confirmed the Audit Committee has wrapped its independent investigation into allegations raised in a prior short-seller report.
For the quarter, PACS reported:
- Net income: $52.3M
- Adjusted EBITDA: $131.5M
- Adjusted EBITDAR: $226.6M
Year-to-date revenue reached $3.93B, up 36%, supported by industry-leading occupancy, 94.8% in mature facilities versus an industry average near 79%.
CEO Jason Murray emphasized the company’s momentum, stating that the performance validates PACS core strengths, adding that PACS now moves forward “with a strong financial foundation, enhanced controls and an even stronger conviction in our ability to drive meaningful growth.”
Interim CFO Mark Hancock highlighted ongoing improvements in governance and internal controls, noting PACS’ “locally-led, centrally-supported model” as a key driver of performance.
PACS provided FY2025 guidance of $5.25B–$5.35B in revenue and $480M–$490M in Adjusted EBITDA as its footprint expands to 320 operations across 17 states.
Abbott (NYSE:ABT) to Acquire Exact Sciences (NASDAQ:EXAS) in $21B Cancer Diagnostics Mega-Deal
The healthcare sector is set to dominate headlines after Abbott announced a definitive agreement to acquire Exact Sciences for $105 per share in cash, valuing the leader in cancer screening and precision oncology at ~$21 billion.
The acquisition brings Abbott into one of the fastest-growing markets in global diagnostics, adding Exact’s portfolio of flagship products including Cologuard®, Oncotype DX®, Oncodetect
, and Cancerguard.
Abbott CEO Robert B. Ford said Exact’s “innovation, its strong brand and customer-focused execution are unrivaled,” calling the deal aligned with Abbott’s mission to take on the “world’s most challenging health issues.”
Exact Sciences CEO Kevin Conroy emphasized the deal’s global reach and impact potential, noting, “Together with Abbott, we can reach more patients, advance earlier detection, and deliver answers that change lives.”
The transaction, expected to close in Q2 2026, will fold Exact into Abbott’s diagnostics business, which will exceed $12B in annual sales after completion.
Kraig Biocraft Laboratories (OTCQB:KBLB) Kicks Off Spider Silk Commercialization with First Major Apparel Order
Kraig Biocraft Laboratories announced a pivotal commercialization milestone, confirming it is now fulfilling an order for customized recombinant spider silk yarns for a globally recognized performance sports apparel brand under a confidential pilot development program.
The order marks one of the most significant steps in KBLB’s history, validating its position as the first and only company to produce scalable, high-performance recombinant spider silk via traditional sericulture.
CEO Kim Thompson said the collaboration reflects “the growing recognition of our material’s potential in high-value, high-performance applications,” positioning the company at the forefront of technical and next-gen textile innovation.
KBLB continues expanding production capabilities across Southeast Asia while advancing additional projects, including ongoing specialty fiber production for a leading European fashion house.
authID (NASDAQ:AUID) Joins NVIDIA (NASDAQ:NVDA) Connect, Anchoring Identity Security to the Emergence of Agentic AI
authID announced it has joined the NVIDIA Connect Program, gaining access to advanced GPU frameworks as the company scales its biometric security and identity-anchoring architecture for AI agents.
CEO Rhon Daguro called Connect “where the next generation of AI innovation is being shaped,” adding that authID is closing the critical gap in Agentic AI governance, enabling enterprises to authenticate and monitor both human and AI agents with auditable rigor.
The move accelerates development of GPU-powered biometric engines and policy frameworks, including the Company’s recently announced authID Mandate governance system.
For more information about Kraig Labs’ spider silk technology and partnership opportunities, visit www.kraiglabs.com
Please click here to read the full Kraig Labs analyst report on 247marketnews.com.
For more information, please visit: www.kraiglabs.com
Contact [email protected] for Analyst Report coverage and other investor/public relations services.
PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 247 is a third-party media provider and has been compensated for providing ongoing KBLB market outreach and other services. This press release may include technical analysis and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions. Please review 247’s Full Disclaimer https://www.247marketnews.com/disclaimer/. Please go to https://247marketnews.com/kblb-disclosure/ for further KBLB and 247marketnews.com disclosure information.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.
The post Deals, Diagnostics & Comebacks appeared first on 24/7 MarketNews.